Abstract
About this talk
Objective: Our main aim is to assess relative efficacy and safety of co-amoxiclav (amoxicillin/clavulanic acid), cefpodoximeproxetil and levofloxacin monotherapy for the treatment of acute, uncomplicated bacterial tonsillitis.
Methods: As this was a prospective, open-label, parallel-group study of 90 patients with acute uncomplicated bacterial tonsillitis were randomly assigned to one of three treatment groups: co-amoxiclav 625 mg thrice daily, cefpodoximeproxetil 200 mg twice daily, or levofloxacin 500 mg once daily for five days. Subjective clinical improvement at the conclusion of therapy was used to measure effectiveness. Adverse occurrences were monitored throughout the trial duration to ensure safety. Results: On days 3 and 7, co-amoxiclav, cefpodoximeproxetil, and levofloxacin all had similar clinical responses; however, on day 5, levofloxacin had a much lower cure rate but a greater improvement rate than co-amoxiclav and cefpodoximeproxetil. At week 1, the bacterial responses were comparable in all three groups. All of the medications were well tolerated, with just a few self-limiting side effects. Conclusions: In cases of acute, simple bacterial tonsillitis, co-amoxiclav, cefpodoximeproxetil, and levofloxacin all demonstrated equivalent clinical and bacteriological cures along with favourable safety profiles.
Speaker
About the speaker
